Strategic Reprioritization and Partnership with Gilead Sciences Propel Xilio’s Innovative Oncology Pipeline
Xilio Therapeutics (XLO), a leading biotechnology firm specializing in tumor-activated immuno-oncology treatments, has announced a strategic reprioritization of its portfolio. The company is focusing on advancing clinical-stage programs for XTX301 and XTX101, two promising therapies targeting cancerous tumors. This decision follows the successful procurement of funds through a private investment in public equity financing, with an anticipated cash runway extending into the second quarter of 2025.
The reprioritization involves leveraging the company’s innovative research platform for tumor-activated bispecific and cell engager molecules, aiming to maximize therapeutic efficacy in cancer treatment. Additionally, Xilio reported additional Phase 2 data for XTX202, supporting its potential as a combination therapy. Consequently, the company plans to discontinue monotherapy development and explore collaboration opportunities to further its development efforts.
With a recent exclusive license agreement with Gilead Sciences for its tumor-activated IL-12 program, including XTX301, Xilio is poised for significant advancement in the field of cancer immunotherapy. This agreement provides substantial upfront payments, potential milestone payments, and royalties on future sales, further strengthening Xilio’s position in the oncology market.
You might like this article:Home Depot Makes Historic $18.25 Billion Acquisition of SRS Distribution
